ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

Mr. Lundstrom has established global business leadership in transgenic animals for discovery of human therapeutic antibodies with Ligand Pharmaceuticals Inc.

ImmunoPrecise Antibodies Appoints Dr. Stefan Lang as Chief Business Officer

Dr. Lang brings extensive background knowledge in the therapeutic antibody sector including corporate strategy, R&D innovation, sales and business development.

Talem Therapeutics Enters into an LOI with AgonOx Pharma

AgonOx specializes in identifying and developing immuno-oncology therapeutics.

ImmunoPrecise Launches Abthena Bispecific Platform And Artemis Intelligence Metadata (AIM)

IPA has designed an advanced discovery platform for bispecific antibodies with validated binding attributes

ImmunoPrecise Antibodies' Annual Revenues Increase 100% to $10,926,268 Million.

Revenue ImmunoPrecise achieved record annual revenue of $10,926,268 in fiscal 2019.

Items 1 to 6 of 71 total

Show per page